BG Medicine (BGMD) Announces Agreement With Kindstar Diagnostics Which Will Provide Galectin-3 Testing Services in China  
10/24/2012 8:31:39 AM

WALTHAM, Mass., Oct. 24, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it has entered into an agreement with Kindstar Diagnostics Co. Ltd., the largest esoteric diagnostic testing business in China, that will enable Kindstar to offer galectin-3 testing services for heart failure management in China. In the US, the BGM Galectin-3® test is cleared by the FDA as an aid in assessing the prognosis of patients with chronic heart failure.